Research background · Updated November 1, 2026
CJC-1295 no DAC Research: Publications, Study Types and Background
Short answer
CJC-1295 no DAC is listed as modified analogue of growth hormone-releasing hormone (GHRH), without the drug affinity complex (DAC). As of November 1, 2026, PubMed indexes 36 records matching CJC-1295 no DAC, the earliest from 2005; 7 were published in 2021–2025 and 11 are reviews. ClinicalTrials.gov lists 1 registered study matching the compound.
- PubMed records
- 36
- Earliest record
- 2005
- Published 2021–2025
- 7
- Reviews
- 11
- Animal-only studies
- 5
- Registered studies
- 1
Publications per year, 2006–2025
17 records in 2016–2025 against 11 in 2006–2015; the busiest year was 2006, with 3.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 3 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 0 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Study types
| All PubMed records | 36 |
|---|---|
| Reviews | 1131% |
| Animal studies (no human subjects indexed) | 514% |
| Indexed as clinical trials | 26% |
| Registered on ClinicalTrials.gov | 1 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 5 of the most-cited and most recent CJC-1295 no DAC papers report, in their own authors’ terms. Each line links the paper it came from.
This narrative review covers unregulated peptides marketed as research compounds, including CJC-1295 with and without DAC, contrasts published clinical evidence with online protocols, and summarizes reported adverse effects such as endocrine and metabolic disturbances and fluid retention.
ReviewDominikowski A 2026Frontiers in endocrinologyPMID 42395176
This narrative review reports that growth hormone secretagogues reliably increase growth hormone and IGF-1, but evidence for improved function or quality of life remains limited, and notes that CJC-1295 remains accessible through unregulated markets, raising product quality and safety concerns.
ReviewVasylieva V 2026Sexual medicine reviewsPMID 42862021
This narrative review of approved and unapproved peptides in sports medicine, including CJC-1295, states that many unapproved peptides show favorable outcomes in animal models but rigorous human safety data are scarce, with potential for serious harm to patients.
ReviewMendias CL 2026Sports medicine (Auckland, N.Z.)PMID 41966639
In a doping-control method study, intact CJC-1295 and other GHRH analogues were detected in rat plasma samples using immunoaffinity purification and high-resolution mass spectrometry; the authors note further studies are needed on species differences in metabolism and elimination.
RatsKnoop A 2016Analytical and bioanalytical chemistryPMID 26879649
In mutant mice lacking brain M3 muscarinic receptors, which showed a dwarf phenotype with pituitary hypoplasia, CJC-1295 was reported to rescue the growth deficit by restoring normal pituitary size and normal serum GH and IGF-1 levels.
MiceGautam D 2009Proceedings of the National Academy of Sciences of the United States of AmericaPMID 19332789
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 36 of the 36 records. They describe what the literature is about, not what CJC-1295 no DAC does.
- Growth Hormone-Releasing Hormone13 papers
- Doping in Sports8 papers
- Substance Abuse Detection7 papers
- Performance-Enhancing Substances6 papers
- Human Growth Hormone3 papers
- Insulin-Like Growth Factor I3 papers
- Horses3 papers
- Tandem Mass Spectrometry3 papers
Key papers
Earliest indexed record
Jetté L (2005). Endocrinology.
PMID 15817669Most-cited paper · 77 citations
Thomas A (2012). Methods (San Diego, Calif.).
PMID 21871962Most-cited #2 · 51 citations
Henninge J (2010). Drug testing and analysis.
PMID 21204297Most-cited #3 · 34 citations
Jetté L (2005). Endocrinology.
PMID 15817669
Citation counts from NIH iCite, among the 36 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Description | Modified analogue of growth hormone-releasing hormone (GHRH), without the drug affinity complex (DAC) |
|---|
As published by Vanta Labs, with its sources, on the CJC-1295 no DAC page.
How these numbers were counted
- PubMed search, run November 1, 2026:
"CJC-1295"[tiab] OR "CJC 1295"[tiab] OR "modified GRF(1-29)"[tiab] OR "mod GRF 1-29"[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
"CJC-1295"re-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use CJC-1295 no DAC outside a laboratory.
Wholesale supply
CJC-1295 no DAC for research, documented lot by lot.
10mg vials. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
CJC-1295 no DAC research questions
How much research has been published on CJC-1295 no DAC?
PubMed indexes 36 records matching CJC-1295 no DAC (searched November 1, 2026), including 11 reviews and 2 records indexed as clinical trials. 7 were published in the five years 2021–2025.
When was CJC-1295 no DAC first described in the literature?
The earliest PubMed record matching CJC-1295 no DAC is from 2005 (Jetté L, Endocrinology, PMID 15817669).
What topics does the CJC-1295 no DAC literature cover?
The subject headings PubMed indexers most often marked as a main topic of CJC-1295 no DAC papers are Growth Hormone-Releasing Hormone, Doping in Sports, Substance Abuse Detection, Performance-Enhancing Substances. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is CJC-1295 no DAC sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy CJC-1295 no DAC wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.